PD-1/PD-L1信号通路及相关抗体在宫颈癌免疫治疗中的应用  

PD-1/PD-L1 signaling pathway and the application of its antibody in cervical cancer immunotherapy

作　　者：秦琪 刘朝奇[2] 熊焱强[1,2] 李倩[1,2] 李志英[1] 

机构地区：[1]三峡大学附属仁和医院妇产科,宜昌443001 [2]三峡大学肿瘤微环境与免疫治疗湖北省重点实验室,宜昌443002

出　　处：《生命的化学》2017年第6期992-997,共6页Chemistry of Life

基　　金：湖北省卫生计生西医类一般项目(WJ2015MB178);肿瘤微环境与免疫治疗湖北省重点实验室开放基金(2015KZL06)

摘　　要：程序性死亡蛋白1(PD-1)是T细胞上主要存在的一种抑制性受体,其与程序性死亡配体1(PD-L1)相互作用,可抑制T细胞增殖、活化和细胞因子的分泌。在肿瘤进展中,PD-1/PD-L1信号通路能够抑制T细胞的免疫反应而促进肿瘤免疫逃逸的发生。PD-1及PD-L1作为一种免疫应答的关键调控蛋白,与宫颈癌的发生发展及预后密切相关,PD-1及PD-L1抗体的深入研究将为治疗宫颈癌提供新的分子靶标。本文就PD-1/PD-L1生物学结构功能、在肿瘤的发生发展中的作用及其抗体在宫颈癌免疫治疗中的应用前景作一简要综述。Programmed cell death protein 1（PD-1） is an inhibitory receptor present on T cells, which interacts with programmed death ligand 1（PD-L1） to inhibit the proliferation, activation and secretion of cytokines. In tumor progression, PD-1/PD-L1 signaling pathway can inhibit the immune response of T cells and promote the occurrence of tumor immune escape. PD-1 and PD-L1 as a key protein in the regulation of immune response, which is closely related with the occurrence, development and prognosis of cervical cancer, and further study of PD-1 and PD-L1 antibodies will provide new molecular targets for the treatment of cervical cancer. In this paper, we will review the biological structure and function of PD-1/PD-L1 and its role in the genesis and development of tumor and the prospect of its application in the treatment of cervical cancer.

关 键 词：程序性死亡蛋白1 程序性死亡配体1 宫颈癌 肿瘤免疫逃逸 免疫治疗 

分 类 号：R737.33[医药卫生—肿瘤]